NATCO Pharma

August 25, 2016

Teva holds cracking door on Copaxone generics

August 24, 2015

16 months on, Novartis sees Arzerra’s multiple sclerosis value

April 17, 2015

After seven years will Momenta and Sandoz wait any longer?

April 01, 2014

Copaxone not dead yet as Teva appeal lives on

December 11, 2013

Teva puts generic Copaxone threat at $550m, but impact could be greater

July 29, 2013

Court accelerates countdown to generic Copaxone launch

June 25, 2012

Teva’s Copaxone headache gets two-year reprieve

June 15, 2012

Gala could lengthen Copaxone’s life but litigation and competitors threaten

January 19, 2012

Big pharma's key events for the next six months

August 22, 2011

Event – Teva needs Copaxone patent victory

July 14, 2008

Teva sees tables turned over Copaxone